BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Esperance Pharmaceuticals, Inc. 

Louisiana Emerging Technology Center
340 East Parker Boulevard
Baton Rouge  Louisiana  70803  U.S.A.
Phone: n/a Fax: 225-615-8952


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Esperance Pharmaceuticals, Inc. Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer 8/28/2012 10:50:38 AM    More...
Esperance Pharmaceuticals, Inc. Presents Results From Phase 1 Study of EP-100 in Advanced, Refractory LHRH-Receptor Expressing Solid Tumors at American Society of Clinical Oncology 6/4/2012 10:32:46 AM    More...
Esperance Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of its Novel Membrane-disrupting Agent, EP-100, in Patients with Advanced Ovarian Cancer 5/18/2012 10:57:07 AM    More...
Esperance Pharmaceuticals, Inc. Presents Poster at American Association for Cancer Research Annual Meeting Demonstrating Synergy of Lead Candidate EP-100 with Paclitaxel in In Vitro Studies 4/3/2012 11:15:25 AM    More...
Esperance Pharmaceuticals, Inc. Completes $7.5 Million Series B Financing 6/1/2011 6:35:34 AM    More...
Third Candidate from <Esperance Pharmaceuticals, Inc.'s Targeted Anti-cancer Platform, EP-302, Establishes Preclinical Proof of Concept 4/21/2010 10:06:02 AM    More...
Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer 9/10/2009 8:05:35 AM    More...
First Candidate from Esperance Pharmaceuticals's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 4/22/2009 8:29:38 AM    More...
Esperance Pharmaceuticals Brings Series A To $14 Million 2/6/2009 11:05:35 AM    More...
Esperance Pharmaceuticals Closes $9 Million Series A Funding 10/31/2006 9:47:03 AM    More...

//-->